Audentes Therapeutics, Inc. (NASDAQ:BOLD) SVP David Nagler sold 3,750 shares of the company’s stock in a transaction dated Wednesday, September 27th. The stock was sold at an average price of $30.00, for a total transaction of $112,500.00. Following the completion of the sale, the senior vice president now directly owns 3,750 shares of the company’s stock, valued at approximately $112,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

David Nagler also recently made the following trade(s):

  • On Friday, September 15th, David Nagler sold 3,750 shares of Audentes Therapeutics stock. The stock was sold at an average price of $25.00, for a total transaction of $93,750.00.

Shares of Audentes Therapeutics, Inc. (BOLD) traded down 5.66% during midday trading on Friday, reaching $28.01. 281,147 shares of the company’s stock traded hands. The stock’s 50 day moving average price is $24.77 and its 200 day moving average price is $24.77. Audentes Therapeutics, Inc. has a 52-week low of $13.13 and a 52-week high of $29.59. The firm’s market capitalization is $778.23 million.

Audentes Therapeutics (NASDAQ:BOLD) last posted its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.10). On average, equities research analysts anticipate that Audentes Therapeutics, Inc. will post ($3.50) EPS for the current fiscal year.

WARNING: This report was first posted by Watch List News and is owned by of Watch List News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.watchlistnews.com/audentes-therapeutics-inc-bold-svp-david-nagler-sells-3750-shares-of-stock/1599385.html.

Several equities research analysts recently weighed in on BOLD shares. Zacks Investment Research raised shares of Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a report on Monday, July 17th. ValuEngine raised shares of Audentes Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, July 20th. Evercore ISI started coverage on shares of Audentes Therapeutics in a report on Wednesday, August 16th. They issued an “outperform” rating and a $23.00 price objective for the company. Finally, Bank of America Corporation reaffirmed a “buy” rating and issued a $33.00 price objective (up previously from $23.00) on shares of Audentes Therapeutics in a report on Friday, September 22nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $24.17.

A number of institutional investors have recently bought and sold shares of the stock. Ardsley Advisory Partners boosted its holdings in Audentes Therapeutics by 59.7% in the second quarter. Ardsley Advisory Partners now owns 20,072 shares of the biotechnology company’s stock valued at $384,000 after acquiring an additional 7,500 shares during the last quarter. California State Teachers Retirement System boosted its holdings in Audentes Therapeutics by 128.8% in the second quarter. California State Teachers Retirement System now owns 27,000 shares of the biotechnology company’s stock valued at $517,000 after acquiring an additional 15,200 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Audentes Therapeutics by 1,086.0% in the second quarter. The Manufacturers Life Insurance Company now owns 13,580 shares of the biotechnology company’s stock valued at $260,000 after acquiring an additional 12,435 shares during the last quarter. Redmile Group LLC boosted its holdings in Audentes Therapeutics by 77.8% in the second quarter. Redmile Group LLC now owns 1,459,616 shares of the biotechnology company’s stock valued at $27,922,000 after acquiring an additional 638,780 shares during the last quarter. Finally, State Street Corp boosted its holdings in Audentes Therapeutics by 231.6% in the second quarter. State Street Corp now owns 221,276 shares of the biotechnology company’s stock valued at $4,234,000 after acquiring an additional 154,544 shares during the last quarter. Institutional investors and hedge funds own 77.01% of the company’s stock.

About Audentes Therapeutics

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Insider Buying and Selling by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.